{"id":"W4402561493","doi":"10.1016/j.annonc.2024.08.184","title":"241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Association of Schools and Colleges of Optometry; Chugai Pharmaceutical; Samsung; European Society for Medical Oncology; Astellas Pharma; Eisai; Genentech; Veracyte; Sociedad Española de Oncología Médica; BeiGene; Mylan; Japanese Breast Cancer Society; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; F. Hoffmann-La Roche; Relay Therapeutics; Seagen; Roche; Celgene; Novartis; Amgen; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Palbociclib; Placebo; Oncology; Internal medicine; Breast cancer; Disease; Overall survival; Cancer; Surgery; Metastatic breast cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322738,0.0009369342,0.001876396,0.0003213955,0.0002389476,0.001250106,0.0006808225,0.001098316,0.008894462],"category_scores_gemma":[0.001820842,0.0002771338,0.003147536,0.0004286871,0.0004145374,0.0009188824,0.0003463723,0.002873202,0.0008234724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009652643,"about_ca_system_score_gemma":0.0006319823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001611703,"about_ca_topic_score_gemma":0.003777852,"domain_scores_codex":[0.9994261,0.0003082829,0.00003053238,0.00008834762,0.00005617601,0.00009049552],"domain_scores_gemma":[0.9992084,0.0003378747,0.0001797976,0.00006074901,0.00005485772,0.0001583537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9195747,0.001169851,0.003976191,0.00169358,0.008300648,0.0001276968,0.00003692485,0.001968268,0.002640614,0.0002973849,0.007329701,0.0528845],"study_design_scores_gemma":[0.7981981,0.09252217,0.07189102,0.0005434665,0.01610537,0.0003982127,0.0001160685,0.002940934,0.002049637,0.001871775,0.01326333,0.00009989976],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9156631,0.04072484,0.0008592555,0.003582824,0.001414033,0.001220985,0.01923393,0.000231025,0.01707022],"genre_scores_gemma":[0.9712628,0.006215547,0.0005686725,0.002281853,0.0005774837,0.0008214617,0.0109959,0.00004188838,0.007234371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008894462,"threshold_uncertainty_score":0.029755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.036486052286007,"score_gpt":0.3264524203934785,"score_spread":0.2899663681074716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}